Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Functional states of myeloid cells in cancer
Lilian van Vlerken-Ysla, Yulia Y. Tyurina, Valerian E. Kagan, et al.
Cancer Cell (2023) Vol. 41, Iss. 3, pp. 490-504
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

The cancer-immunity cycle: Indication, genotype, and immunotype
Ira Mellman, Daniel S. Chen, Thomas Powles, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2188-2205
Open Access | Times Cited: 345
Myeloid-derived suppressor cells in cancer and cancer therapy
Samantha Lasser, Feyza Gül Özbay Kurt, Ihor Arkhypov, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 2, pp. 147-164
Closed Access | Times Cited: 116
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives
Hao Lin, Chaxian Liu, An-Kang Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 59
Modulation of macrophage metabolism as an emerging immunotherapy strategy for cancer
Corey Dussold, Kaylee Zilinger, Jillyn Turunen, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 2
Open Access | Times Cited: 17
The heterogeneity of neutrophils in cancer and its implication for therapeutic targeting
Evgeniy Eruslanov, Yulia Nefedova, Dmitry I. Gabrilovich
Nature Immunology (2025) Vol. 26, Iss. 1, pp. 17-28
Closed Access | Times Cited: 2
Myeloid cell-derived apCAFs promote HNSCC progression by regulating proportion of CD4+ and CD8+ T cells
Feilong Ren, Lin Meng, Shize Zheng, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access | Times Cited: 2
Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies
Ibraheem Nasir, Conor McGuinness, Ashleigh R. Poh, et al.
Trends in Immunology (2023) Vol. 44, Iss. 12, pp. 971-985
Open Access | Times Cited: 36
Glutamine metabolic competition drives immunosuppressive reprogramming of intratumour GPR109A+myeloid cells to promote liver cancer progression
Yang Yang, Tianduo Pei, Chaobao Liu, et al.
Gut (2024), pp. gutjnl-332429
Closed Access | Times Cited: 11
MOFs‐Based Magnetic Nanozyme to Boost Cascade ROS Accumulation for Augmented Tumor Ferroptosis
Ying Yuan, Bo Chen, Xingxing An, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 20
Closed Access | Times Cited: 10
Epigenetic regulation of tumor immunity
Lizhi Pang, Fei Zhou, Yang Liu, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 12
Open Access | Times Cited: 8
Complement C3 of tumor-derived extracellular vesicles promotes metastasis of RCC via recruitment of immunosuppressive myeloid cells
Yibi Zhang, Xiaodong Wang, Yinmin Gu, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 4
Open Access | Times Cited: 1
SPP1 macrophages across diseases: A call for reclassification?
Alessio Reggio, Claudia Fuoco, Rebecca Deodati, et al.
The FASEB Journal (2025) Vol. 39, Iss. 5
Open Access | Times Cited: 1
Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?
Daisy Bhatia, Riccardo Dolcetti, Roberta Mazzieri
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access | Times Cited: 1
Targeting cGAS/STING signaling-mediated myeloid immune cell dysfunction in TIME
Vijay Kumar, Caitlin Bauer, John H. Stewart
Journal of Biomedical Science (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 16
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands
Kelly Boelaars, Yvette van Kooyk
Trends in cancer (2023) Vol. 10, Iss. 3, pp. 230-241
Open Access | Times Cited: 16
Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade
Cassia Wang, Lee Chen, Doris Fu, et al.
Clinical & Experimental Metastasis (2024) Vol. 41, Iss. 4, pp. 333-349
Open Access | Times Cited: 7
Oral administration of Manuka honey induces IFNγ-dependent resistance to tumor growth that correlates with beneficial modulation of gut microbiota composition
Razan J. Masad, Ienas Idriss, Yassir A. Mohamed, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 7
Mechanisms by which obesity regulates inflammation and anti-tumor immunity in cancer
Cora E Miracle, Chelsea L. McCallister, Richard D Egleton, et al.
Biochemical and Biophysical Research Communications (2024) Vol. 733, pp. 150437-150437
Closed Access | Times Cited: 6
Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment
Yucheng Zheng, Rongwei Xu, Xu Chen, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 10
Open Access | Times Cited: 6
Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance
Yumin Fu, Xinyu Guo, Linmao Sun, et al.
eLife (2024) Vol. 13
Open Access | Times Cited: 5
Recent developments in myeloid immune modulation in cancer therapy
Sepideh Parvanian, Xinying Ge, Christopher Garris
Trends in cancer (2025)
Closed Access
Blockade of TIPE2-Mediated Ferroptosis of Myeloid-Derived Suppressor Cells Achieves the Full Potential of Combinatory Ferroptosis and Anti-PD-L1 Cancer Immunotherapy
Hina Tariq, Zihao Liang, Lawan Rabiu, et al.
Cells (2025) Vol. 14, Iss. 2, pp. 108-108
Open Access
Single-cell transcriptomics unveils multifaceted immune heterogeneity in early-onset versus late-onset cervical cancer
Qian Chen, Dongfeng Deng, Hong Zhu, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer
Yuqi Feng, Letian Fang, Guangwen Cao
Hepatoma Research (2025)
Open Access
Self-assembled HO-1i-Pt(IV) nanomedicine targeting p38/MAPK and MDR pathways for cancer chemo-immunotherapy
Xiaomeng Liu, Zhe Li, Xiaoya Wang, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 797-813
Closed Access
Page 1 - Next Page

Scroll to top